Zhang Heyu, Ma Xi, Peng Saihui, Nan Xu, Zhao Hongshan
Department of Immunology, School of Basic Medical Sciences, Peking University No. 38 Xueyuan Road, Beijing, PR China ; Human Disease Genomics Center, Peking University 38 Xueyuan Road, Beijing, PR China ; Central Laboratory, Peking University School of Stomatology 22 South Zhongguancun Road, Beijing, PR China.
State Key Lab of Animal Nutrition, China Agricultural University 2 Yuanmingyuan West Road, Beijing 100193, PR China.
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8105-11. eCollection 2014.
Both benign prostatic hyperplasia (BPH) and prostate cancer (PC) are common diseases for men around the world. Both serine/threonine protein kinase MST4 (MST4) and serine/threonine kinase 25 (STK25) belong to the Ste20-like kinases and interact with programmed cell death 10 (PDCD10) which is closely linked to cancer diseases. To clarify the roles of MST4, STK25 and PDCD10 in prostate carcinogenesis, we examined MST4, STK25 and PDCD10 expression in tissue microarray blocks containing 110 cores of BPH and 160 cores of PC immunohistochemically and evaluated their correlation with clinicopathological findings. MST4 was not expressed in all the BPH cases and expressed in 38.7% of PC cases (P < 0.0001). STK25 expression was found in 77.3% of BPH cases and 93.1% of PC cases (P < 0.0001). PDCD10 staining was considered weak in 82 (74.5%) and strong in 28 (25.5%) of BPH cases. However, in prostate cancer cases, PDCD10 staining was weak in 95 (59.4%) and strong in 65 (40.6%) (P < 0.05). PDCD10 and STK25 immunostaining were associated with age in prostatic hyperplasia cases (P < 0.05). The staining intensity for STK25 was significantly greater in Gleason grades 3-5 (47.1% of such cases staining strongly) compared with other grades of prostate cancer (only 26.5% of these cases staining strongly; P < 0.05). Our results suggest that MST4, STK25 and PDCD10 are unregulated in prostate cancer and may play roles in prostate tumorigenesis. MST4 may be a helpful marker for identifying prostate cancer.
良性前列腺增生（BPH）和前列腺癌（PC）都是全球男性的常见疾病。丝氨酸/苏氨酸蛋白激酶MST4（MST4）和丝氨酸/苏氨酸激酶25（STK25）都属于Ste20样激酶，并与程序性细胞死亡10（PDCD10）相互作用，而程序性细胞死亡10与癌症疾病密切相关。为了阐明MST4、STK25和PDCD10在前列腺癌发生中的作用，我们通过免疫组织化学方法检测了包含110个BPH核心和160个PC核心的组织微阵列块中MST4、STK25和PDCD10的表达，并评估了它们与临床病理结果的相关性。MST4在所有BPH病例中均未表达，而在38.7%的PC病例中表达（P<0.0001）。STK25表达在77.3%的BPH病例和93.1%的PC病例中被发现（P<0.0001）。在BPH病例中，82例（74.5%）的PDCD10染色被认为较弱，28例（25.5%）较强。然而，在前列腺癌病例中，95例（59.4%）的PDCD10染色较弱，65例（40.6%）较强（P<0.05）。在前列腺增生病例中，PDCD10和STK25免疫染色与年龄相关（P<0.05）。与其他前列腺癌分级相比，Gleason分级为3-5级的病例中STK25的染色强度明显更高（此类病例中有47.1%染色强烈）（其他分级的病例中只有26.5%染色强烈；P<0.05）。我们的结果表明，MST4、STK25和PDCD10在前列腺癌中表达失调，可能在前列腺肿瘤发生中起作用。MST4可能是识别前列腺癌的一个有用标志物。
